2 terminated, 1 not yet recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Nucleobindins: new trials by email Literature Review of Nucleobindins trials Research Report on Nucleobindins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg PegIFN alfa-2b, PegIFN alfa-2b and NUC - Chronic Hepatitis B | Phase 4 | Not yet recruiting | Huashan Hospital | 360 | 2025-04-01 | 2025-03-28 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment - Chronic Hepatitis B | Phase 1 | Terminated | Hoffmann-La Roche | 60 | 2023-04-28 | 2026-01-22 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 64 | 2019-06-18 | 2020-07-22 |
Hepatitis B, Chronic (3) · Hepatitis B (1)
F-star Therapeutics, Inc. (1) · Hoffmann-La Roche (1) · Huashan Hospital (1)
Canada (1) · China (1) · Hong Kong (1) · New Zealand (1) · South Korea (1) · Spain (1) · Taiwan (1) · Thailand (1) · United Kingdom (1) · United States (1)
Don Mitchell (1)